The DoverPac story: what increased HPAPI usage means for containment systems
The rising use of high-potency active pharmaceutical ingredients (HPAPIs) in drug development, driven largely by growing demand for targeted oncology…
Powder Handling
In association with ILC Dover
Single-use isolation technology for safe handling of oxygen sensitive materials
ILC Dover’s recent webinar discussed the biopharma containment company’s range of specialised flexible isolator solutions designed for safe handling of…
Latest News
View MoreHow single-use FIBC containment systems can work for you
DoverPac® Containment Systems are the global standard for disposable process and powder containment systems. In 1997, ILC Dover worked in collaboration with Eli Lilly to develop a flexible intermediate…
High containment for lyophilisation processes
The growth of lyophilisation and its complicated processes has challenged manufacturers to maintain safety for operators working with highly potent ingredients, which has created a…
The benefits of single-use plastics versus reusable systems in upstream processes
For years pharmaceutical manufacturers have invested in rigid stainless steel equipment for upstream processing. While this traditional approach made sense…
To clean or not to clean? Why single use is better for pharma HPAPI containment
Pharmaceutical drug development is continually challenged to provide better compounds to treat a wide range of disease and illness. In…
How CMO/CDMO facilities can gain value with single use containment
The last few years have proven pivotal for contract manufacturing and development organisations (CMOs and CDMOs). With rapid development in…
HPAPI: Dealing with containment challenges
As a result of advances in clinical pharmacology and oncology research, highly potent active pharmaceutical ingredients (HPAPIs) have experienced a…
